In vitro chemosensitivity of head and neck cancer cell lines

European Journal of Medical Research

TK Hoffmann²  H Bier³  TL Whiteside⁵  S Lang²  S Brandau²  AE Albers¹  S Mattheis²  G Lehnerdt²  E Bölke⁴  C Bergmann²  M Bas³  J Greve²  S Trellakis²  PJ Schuler⁵ 

[1] Hals-Nasen-Ohrenklinik, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany;Hals-Nasen-Ohrenklinik, Universität Duisburg-Essen, Essen;Hals-Nasen-Ohrenklinik, Technische Universität München, Klinikum Rechts der Isar, München;Klinik für Strahlentherapie und Radiologische Onkologie, Heinrich-Heine-Universität, Düsseldorf;Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA

关键词: MTT;    Cell line;    Chemosensitivity;    Chemotherapy;    Head and neck cancer;   

Others  :  1093211
DOI  :  10.1186/2047-783X-15-8-337

 received in 2010-05-14, accepted in 2010-06-17,  发布年份 2010

【 摘 要 】

Background

Systemic treatment of head and neck squamous cell carcinoma (HNSCC) includes a variety of antineoplastic drugs. However, drug-resistance interferes with the effectiveness of chemotherapy. Preclinical testing models are needed in order to develop approaches to overcome chemoresistance.

Methods

Ten human cell lines were obtained from HNSCC, including one with experimentally-induced cisplatin resistance. Inhibition of cell growth by seven chemotherapeutic agents (cisplatin, carboplatin, 5- fluorouracil, methotrexate, bleomycin, vincristin, and paclitaxel) was measured using metabolic MTT-uptake assay and correlated to clinically-achievable plasma concentrations.

Results

All drugs inhibited cell growth in a concentration-dependent manner with an IC50 comparable to that achievable in vivo. However, response curves for methotrexate were unsatisfactory and for paclitaxel, the solubilizer cremophor EL was toxic. Cross-resistance was observed between cisplatin and carboplatin.

Conclusion

Chemosensitivity of HNSCC cell lines can be determined using the MTT-uptake assay. For DNA-interfering cytostatics and vinca alkaloids this is a simple and reproducible procedure. Determined in vitro chemosensitivity serves as a baseline for further experimental approaches aiming to modulate chemoresistance in HNSCC with potential clinical significance.

【 授权许可】

   
2010 I. Holzapfel Publishers

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Oddone N, Morgan GJ, Palme CE, et al.: Metastatic cutaneous squamous cell carcinoma of the head and neck: the immunosuppression, treatment, extranodal spread, and margin status (ITEM) prognostic score to predict outcome and the need to improve survival. Cancer 2009, 9:1883-1891.
• [2]Ahmed SM, Cohen EE: Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors. Curr Cancer Drug Targets 2007, 7:666-673.
• [3]Dollner R, Granzow C, Neudert M, Dietz A: Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations. Anticancer Res 2006, 2B:1651-1655.
• [4]Pignon JP, Bourhis J, Domenge C, Designe L: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000, 9208:949-955.
• [5]Schrag D, Garewal HS, Burstein HJ, Samson DJ, von Hoff DD, Somerfield MR: American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004, 17:3631-3638.
• [6]Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA: Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol 1981, 11:703-710.
• [7]Bier H, Bergler W, Mickisch G, Wesch H, Ganzer U: Establishment and characterization of cisplatin-resistant sublines of the human squamous carcinoma cell line HLac 79. Acta Otolaryngol 1990, 5-6:466-473.
• [8]Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987, 4:936-942.
• [9]Poch G, Vychodil-Kahr S, Petru E: Sigmoid model versus median-effect analysis for obtaining dose-response curves for in vitro chemosensitivity testing. Int J Clin Pharmacol Ther 1999, 4:189-192.
• [10]Hafner D, Heinen E, Noack E: Mathematical analysis of concentration-response relationships. Method for the evaluation of the ED50 and the number of binding sites per receptor molecule using the logit transformation. Arzneimittelforschung 1977, 10:1871-1873.
• [11]Scheithauer W, Clark GM, Salmon SE, Dorda W, Shoemaker RH, Von Hoff DD: Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep 1986, 12:1379-1382.
• [12]van den Bongard HJ, Mathot RA, Beijnen JH, Schellens JH: Pharmacokinetically guided administration of chemotherapeutic agents. Clin Pharmacokinet 2000, 5:345-367.
• [13]Rousseau A, Marquet P, Debord J, Sabot C, Lachatre G: Adaptive control methods for the dose individualisation of anticancer agents. Clin Pharmacokinet 2000, 4:315-353.
• [14]Perez-Tomas R: Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006, 16:1859-1876.
• [15]Brower SL, Fensterer JE, Bush JE: The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy. Methods Mol Biol 2008, 57-78.
• [16]Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S: A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 2007, 9:1093-1101.
• [17]Abe R, Ueo H, Akiyoshi T: Evaluation of MTT assay in agarose for chemosensitivity testing of human cancers: comparison with MTT assay. Oncology 1994, 5:416-425.
• [18]Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL: A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007, 15(Pt 1):4345-4354.
• [19]Padron JM, van der Wilt CL, Smid K, et al.: The multilayered postconfluent cell culture as a model for drug screening. Crit Rev Oncol Hematol 2000, 2-3:141-157.
• [20]Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T: The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007, 1:71-83.
• [21]Borst P, Rottenberg S, Jonkers J: How do real tumors become resistant to cisplatin? Cell Cycle 2008, 10:1353-1359.
• [22]Cullen KJ, Newkirk KA, Schumaker LM, Aldosari N, Rone JD, Haddad BR: Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors. Cancer Res 2003, 23:8097-8102.
• [23]Hoffmann TK, Sonkoly E, Hauser U, et al.: Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol 2008, 12:1100-1109.
• [24]Akervall J, Guo X, Qian CN, et al.: Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients. Clin Cancer Res 2004, 24:8204-8213.
• [25]Hasegawa Y, Goto M, Hanai N, et al.: Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 2007, 8:749-756.
• [26]Knox RJ, Friedlos F, Lydall DA, Roberts JJ: Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine (1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 1986, 4(Pt 2):1972-1979.
• [27]Bier H: Chemotherapeutic drug resistance in the management of head and neck cancer. Eur Arch Otorhinolaryngol 1993, 4:200-208.
• [28]Coley HM, Lewandowicz G, Sargent JM, Verrill MW: Chemosensitivity testing of fresh and continuous tumor cell cultures using lactate dehydrogenase. Anticancer Res 1997, 1A:231-236.
• [29]Pagliacci MC, Spinozzi F, Migliorati G, et al.: Genistein inhibits tumour cell growth in vitro but enhances mitochondrial reduction of tetrazolium salts: a further pitfall in the use of the MTT assay for evaluating cell growth and survival. Eur J Cancer 1993, 11:1573-1577.